Telomir Pharmaceuticals (TELO) Research & Development (2023 - 2026)
Telomir Pharmaceuticals (TELO) posted Research & Development of $1.3 million for Q4 2025, up 70.66% sequentially from $759525.0 in Q3 2025, and up 381.71% YoY from $269083.0 in Q4 2024.
Telomir Pharmaceuticals (TELO) Research & Development (2023 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Research & Development for 3 years, with the latest figure at $1.3 million in Q4 2025.
- Quarterly Research & Development rose 381.71% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 6.11% YoY) and the FY2025 annual result came in at $2.4 million, up 8.96% from the prior year.
- Research & Development grew to $1.3 million in Q4 2025 per TELO's latest filing, from $759525.0 in the prior quarter.
- Over five years, Research & Development peaked at $1.3 million in Q4 2025 and troughed at $42839.0 in Q2 2025.
- A 3-year average of $578232.9 and a median of $592100.5 in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 381.71% in 2025, down 92.8% in 2025.
- Over 3 years, Research & Development stood at $479550.0 in 2023, then sank by 43.89% to $269083.0 in 2024, then jumped by 381.71% to $1.3 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $1.3 million, $759525.0, and $42839.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | 444,674.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 444,674.00 |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 759,525.00 |
| Jun 30, 2025 | 42,839.00 |
| Mar 31, 2025 | 336,996.00 |
| Dec 31, 2024 | 269,083.00 |
| Sep 30, 2024 | 627,434.00 |
| Jun 30, 2024 | 594,801.00 |
| Mar 31, 2024 | 804,023.00 |
| Dec 31, 2023 | 479,550.00 |
| Sep 30, 2023 | 589,400.00 |
| Jun 30, 2023 | 698,600.00 |
| Mar 31, 2023 | 440,335.00 |